Due to the worsening COVID-19 pandemic and the related restrictions in all European countries, this year´s CEEGOG meeting is going to be held in the virtual format only.
The meeting is scheduled for December 10, 2021, and will last from 12 p.m. to 4 p.m.The meeting agenda and ZOOM link will be sent out to the CEEGOG members in due time.
We look forward to seeing you all online connected to our annual meeting and to discussing with you the research projects conducted or planned to be conducted under the CEEGOG umbrella!
We would like to invite you to the 12th Prague WORLD INTERDISCIPLINARY ONCOLOGY COLLOQUIUM to be held virtually on January 20 ‒22, 2021. The main topics of the colloquium are as follows: State of the art, ASCO GIT 2020 – Actual Hot News, Oncogynaecology, Breast cancer, Immunotherapy, Gastrointestinal cancer, Genitourinary cancer, Lung cancer, Head and neck cancer.
Sections with presentations given mostly by eminent foreign guests are to be held in English. In case of presentations in Czech simultaneous interpreting into English will be provided for foreign participants.
More information to be found on the following link: https://pragueonco.cz/?lang=en
Unfortunatelly, due to the COVID-19 pandemic and related restrictions in all European countries, we have decided to turn the meeting into a VIRTUAL format only!! The meeting is scheduled to start at 1 p.m., and finish at 5 p.m.
The final agenda and ZOOM access link will be sent out to all CEEGOG members in due time.
Despite the virtual meeting format we hope that you will find the meeting program useful and exciting.
We look forward to seeing you all online connected to our annual meeting!
This year´s CEEGOG meeting will be held in Prague on Monday, December 7, 2020.
You are welcome to send us proposals for new collaborative trials to be included on the agenda. Should you like to share information about your projects and proposal studies with other CEEGOG members, kindly let us know by the end of October.
All your colleagues and study coordinators are cordially welcome as well.
We look forward to meeting with all of you at the scheduled CEEGOG meeting.
CEEGOG has been a provisional member of the Organization of International Cooperative Groups for Clinical Trials in Gynaecologic Cancers (GCIG) since June 2018.
Our provisional GCIG membership was re-evaluated for full membership in June 2020, that is, after two years of provisional membership. One criterion was that CEEGOG must work as a group, which means that several CEEGOG centres have participated in GCIG trials.
During our membership in GCIG, CEEGOG has joined 11 GCIG trials, and the CEEGOG sites have enrolled almost 200 patients in those trials.
I am pleased to announce that CEEGOG has been accepted as a full member of GCIG.
Due to the COVID-19 pandemic, the GCIG Spring meeting was held online as separate respective committee meetings from May 20 to June 13, 2020. CEEGOG was represented by its Chairman, Prof. David Cibula, by the CEEGOG manager, Ivana Nohová, and by Dr Marcin Stanislaw Bobińsky (Medical University of Lublin, Poland), one of the CEEGOG scientific committee members. During the Cervix committee meeting and the Cervix Cancer Research Network meeting, David Cibula introduced the planned CEEGOG trial called CERVANTES (A prospective randomized trial on the role of radical surgery and adjuvant therapy in the management of intermediate / high-risk cervical cancer patients; CEEGOG CX-05). The GCIG meeting audience expressed interest in trial participation.
The autumn GCIG meeting will be held in Leuven, Belgium, on October 12–13, 2020.
On April 3, 2020, a virtual meeting of representatives of the 21 national trial groups was held.
The ENGOT Operational Representatives’ meeting focused on the activity update provided by the Contracts Working Group and the Trial Budgeting Working Group. CEEGOG is a member of the Trial Budgeting working group and actively participates in its projects.
The main topic of the ENGOT assembly meeting dealt with trial activities and the status of ENGOT trials. The ENGOT collaborative group representatives were also updated on the CEEGOG/ENGOT trials ( ABRAX, SENTIX, and FERTISS), and we also presented new information regarding the ENGOT-ov53/Vitalia/SOV09/ trial, for which CEEGOG is the lead group.
Page 1 of 6